Dogs to be treated with human breast cancer drug

pet health monitor

A US study has found that the common cause of lung cancer in dogs appears to be the same gene—HER2—implicated in a particular type of breast cancer diagnosed in many women.

Published in Clinical Cancer Research, researchers from the Translational Genomics Research Institute (TGen), and The Ohio State University, also found that neratinib—a drug that has successfully been used to battle human breast cancer—might also work for many of the nearly 40,000 dogs in the US that annually develop the most common type of canine lung cancer, known as canine pulmonary adenocarcinoma, or CPAC.

Neratinib inhibits a mutant cancer-causing form of the gene HER2, which is common to both CPAC and HER2-positive human breast cancer patients.

“With colleagues at Ohio State, we found a novel HER2 mutation in nearly half of dogs with CPAC,” Dr Will Hendricks said. 

“We now have a candidate therapeutic opportunity for a large proportion of dogs with lung cancer.”

Based on the results from this study, a clinical trial using neratinib is planned for dogs with naturally occurring lung cancer that have the HER2 mutation.

Vet Practice magazine and its associated website is published by Engage Media. All material is protected by copyright and may not be reproduced in any form without prior written permission. Explore how our content marketing agency can help grow your business at Engage Content or at YourBlogPosts.com

Post a Comment

Your email address will not be published. Required fields are marked *

Subscribe to our newsletter

Want stories like this delivered to your inbox? FOR FREE!
SUBSCRIBE!
Give it a try, you can unsubscribe anytime.